Chronic Spontaneous Urticaria Clinical Landscape Report 2026: Trials, Readouts and White Space
Turn fragmented clinical intelligence into a decision-ready landscape. This report was assembled with PatSnap MCP Servers for Clinical Trials, Drug & Asset, and Company & Deal Intelligence. Explore the PatSnap MCP Marketplace to reproduce the workflow in your own AI research stack.
Data snapshot: 16 July 2026. This report is a strategic research view, not medical advice. Trial status and timing can change; confirm records before making development or investment decisions.
Executive view
Chronic Spontaneous Urticaria remains an active clinical development field. Clinical competition is shifting from broad immunosuppression toward pathway-selective control, durable remission and treatment strategies that reduce steroid exposure without trading away safety. The PatSnap evidence set used here contains 198 matched trial records and 186 indexed result records before the decision-focused sample below was selected.
How PatSnap MCP built this report
The workflow used Clinical Trials MCP search to define the landscape, then clinical_trial_fetch to retrieve trial design, phase, status, sponsor, geography, endpoints and timing. It separately called clinical_trial_result_fetch for indexed readouts. Drug & Asset drug_fetch supplied target and global development status, while Company & Deal Intelligence organization_fetch supplied sponsor context. This keeps trial-, asset- and company-level claims distinct and traceable.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Expected readout |
|---|---|---|---|---|---|---|
| NCT07686484 | HRS-3095 | Early Phase 1; Not yet recruiting | Atridia Pty Ltd. | Australia | Safety and Tolerability Based on Incidence and Severity of Treatment Emergent Adverse Events (Day 8) | 2026-10-15 |
| NCT07684560 | Alpha-0261 | Phase 1; Not yet recruiting | Shenzhen Alpha Molecular Technology Co., Ltd. | China | Frequency of treatment emergent adverse events (Part 1: approximately 6 weeks Part 2: approximately 1 week) | 2027-03-30 |
| NCT07680413 | Intervention not normalized | Not Applicable; Recruiting | Bharat Serums & Vaccines Ltd. | India | Change in clinical improvement as assessed by Urticaria Activity Score (UAS7) (End of study, approximately 1 year) | 2026-09-01 |
| CTR20262423 | Alpha-0261 | Phase 1; 进行中 （尚未招募） | Shenzhen Alpha Molecular Technology Co., Ltd. | China | (42天) | Timing not listed |
The table is designed for competitive decisions: endpoint selection, geographic reach and readout timing appear beside phase and sponsor. Phase alone does not reveal evidence maturity; a small study may answer a near-term biomarker question while a large pivotal program can leave a multi-year readout gap.
What indexed results say
- An Open Label Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults With Chronic Inducible Urticaria (Phase 2): the indexed record reports Safety = 3 Participants with a TEAE; -; Safety = 7 Participants with a TEAE.
- Matching-adjusted indirect comparison analysis of omalizumab versus dupilumab in patients with chronic spontaneous urticaria (Phase 3): the indexed record reports ISS7(12-week) = -2.4 Point ( -4.6 to -0.1); ISS7(12-week) = -5.4 Point ( -6.9 to -4.0).
- Efficacy of Remibrutinib versus Dupilumab at Early Timepoints in Chronic Spontaneous Urticaria: US Phase 3b Study Design (RECLAIM) (Phase 3): the indexed record reports AE = 60.0 %; -.
Cross-trial comparisons require caution. Population, prior therapy, baseline risk, endpoint definition, follow-up and analysis set can all change the apparent signal. The strategic value lies in identifying what each readout resolves—and which uncertainty remains.
Build a living clinical map: connect to PatSnap MCP Servers and combine trial design, result, asset and organization records without manually reconciling separate databases.
Asset and sponsor context
PatSnap Drug & Asset records add mechanism and global development status for the sampled programs, including HRS-3095 (Phase 2), Alpha-0261 (Phase 1; MRGPRX2). Company & Deal Intelligence records identify sponsor context for Atridia Pty Ltd., Shenzhen Alpha Molecular Technology Co., Ltd., Bharat Serums & Vaccines Ltd.. Together, those layers show whether a study sits inside a scaled portfolio, an emerging specialist strategy or an academic development path.
Where the white space is
- Standard definitions for steroid-free remission and durable disease control.
- Head-to-head trials against current targeted standards, not placebo alone.
- Biomarker strategies that distinguish mechanistic responders before prolonged treatment.
- Long-term infection, malignancy and immune-reconstitution follow-up.
Strategic implications
For sponsors, differentiation is more credible when the evidence package resolves a known decision gap: an active comparator, a better-defined responder population, a safer or easier delivery model, a clinically meaningful outcome, or a defensible sequencing strategy. Business-development teams can use the same landscape to separate crowded mechanisms from differentiated evidence architectures. Investors should track endpoint maturity and operational feasibility alongside nominal phase.
What to monitor next
Track status changes, protocol amendments, primary-completion dates, newly indexed results, ownership changes and multinational expansion. Re-run the MCP queries on a schedule and compare deltas. Pay particular attention when a program moves from a surrogate endpoint to a clinical outcome or when a specialist sponsor adds a scaled development partner.
Bottom line
Chronic Spontaneous Urticaria has meaningful clinical activity and equally meaningful evidence gaps. A useful landscape connects trial design, results, mechanism and sponsor rather than listing studies in isolation.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and use Clinical Trials, Drug & Asset, and Company & Deal Intelligence as structured building blocks for monitoring and SEO-ready clinical reports.
